---
document_datetime: 2025-10-29 12:58:17
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lytgobi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: lytgobi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.9196844
conversion_datetime: 2025-12-17 15:43:29.237433
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Lytgobi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                    |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0008               | Renewal of the marketing authorisation. | 27/03/2025                          | 02/06/2025                                  |                                  | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     | renewal of the conditional MA for Lytgobi, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.   |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/68/20 2409 | Periodic Safety Update EU Single assessment - futibatinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 08/05/2025 | n/a | PRAC Recommendation - maintenance                                                                                                        |
| PSUSA/68/20 2403 | Periodic Safety Update EU Single assessment - futibatinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 31/10/2024 | n/a | PRAC Recommendation - maintenance                                                                                                        |
| IB/0006/G        | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 13/08/2024 | n/a |                                                                                                                                          |
| IB/0005          | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 26/07/2024 | n/a |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| R/0003           | Renewal of the marketing authorisation.                                                        | 21/03/2024   | 22/05/2024   |             | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Lytgobi, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.   |
|------------------|------------------------------------------------------------------------------------------------|--------------|--------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/68/20 2309 | Periodic Safety Update EU Single assessment - futibatinib                                      | 16/05/2024   | n/a          |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0001          | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 10/10/2023   | 22/05/2024   | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |